Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer.
Adjuvant chemotherapy
Breast cancer
Hypercalciuria
Vitamin D deficiency
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Jul 2021
15 Jul 2021
Historique:
received:
16
03
2021
accepted:
18
06
2021
entrez:
16
7
2021
pubmed:
17
7
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Changes in calcium metabolism and calcium urinary excretion during chemotherapy have not been thoroughly assessed in patients with early breast cancer (EBC), a population who frequently present vitamin D insufficiency. As hypercalciuria is a classical contra-indication to vitamin D (VD) supplementation, this study evaluated changes in VD and calcium metabolism parameters in patients with EBC undergoing adjuvant chemotherapy (CT). In patients with EBC who received six cycles of adjuvant CT, VD and calcium parameters were monitored at inclusion, and then every 3 weeks, at each CT cycle initiation. The primary endpoint was the percentage of patients showing hypercalciuria during adjuvant CT (between Day 1, Cycle 1 [D1C1] and Day 1, Cycle 6 [D1C6]). The primary endpoint could be evaluated in 82 patients. Most patients (n = 66, 80.5%) had VD insufficiency (< 30 ng/mL) at baseline. Hypercalciuria was detected in 29 patients (35.4%; 95% CI: 25.6-46.5) between D1C1 and D1C6, but was not clinically significant in any of the affected patients. The percentage of hypercalciuria events was not different between patients with sufficient and insufficient baseline VD levels (34.8% vs. 37.5%), and between patients who received or not VD supplementation (37.5% vs. 34.5%,). This comprehensive study on VD and calcium parameter changes in patients with EBC during adjuvant chemotherapy shows that hypercalciuria is a frequent abnormality in this setting, although asymptomatic. Therefore, it should not be considered as a limitation for high dose VD supplementation in this population. EudraCT:2014-A01454-43 . Registered 29 august 2016.
Sections du résumé
BACKGROUND
BACKGROUND
Changes in calcium metabolism and calcium urinary excretion during chemotherapy have not been thoroughly assessed in patients with early breast cancer (EBC), a population who frequently present vitamin D insufficiency. As hypercalciuria is a classical contra-indication to vitamin D (VD) supplementation, this study evaluated changes in VD and calcium metabolism parameters in patients with EBC undergoing adjuvant chemotherapy (CT).
METHODS
METHODS
In patients with EBC who received six cycles of adjuvant CT, VD and calcium parameters were monitored at inclusion, and then every 3 weeks, at each CT cycle initiation. The primary endpoint was the percentage of patients showing hypercalciuria during adjuvant CT (between Day 1, Cycle 1 [D1C1] and Day 1, Cycle 6 [D1C6]).
RESULTS
RESULTS
The primary endpoint could be evaluated in 82 patients. Most patients (n = 66, 80.5%) had VD insufficiency (< 30 ng/mL) at baseline. Hypercalciuria was detected in 29 patients (35.4%; 95% CI: 25.6-46.5) between D1C1 and D1C6, but was not clinically significant in any of the affected patients. The percentage of hypercalciuria events was not different between patients with sufficient and insufficient baseline VD levels (34.8% vs. 37.5%), and between patients who received or not VD supplementation (37.5% vs. 34.5%,).
CONCLUSIONS
CONCLUSIONS
This comprehensive study on VD and calcium parameter changes in patients with EBC during adjuvant chemotherapy shows that hypercalciuria is a frequent abnormality in this setting, although asymptomatic. Therefore, it should not be considered as a limitation for high dose VD supplementation in this population.
TRIAL REGISTRATION
BACKGROUND
EudraCT:2014-A01454-43 . Registered 29 august 2016.
Identifiants
pubmed: 34266398
doi: 10.1186/s12885-021-08563-4
pii: 10.1186/s12885-021-08563-4
pmc: PMC8283899
doi:
Substances chimiques
Vitamin D
1406-16-2
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
815Informations de copyright
© 2021. The Author(s).
Références
Ann Oncol. 2016 Jul;27(7):1235-41
pubmed: 27029707
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
Am J Clin Nutr. 1999 May;69(5):842-56
pubmed: 10232622
Menopause. 2014 Nov;21(11):1173-80
pubmed: 24937025
J Pediatr. 1989 May;114(5):793-800
pubmed: 2785592
Ren Fail. 2012;34(3):338-42
pubmed: 22260330
N Engl J Med. 2007 Jul 19;357(3):266-81
pubmed: 17634462
Clin Chem Lab Med. 2009;47(2):120-7
pubmed: 19099529
Eur J Endocrinol. 2003 Sep;149(3):209-13
pubmed: 12943523
Indian J Endocrinol Metab. 2012 May;16(3):409-13
pubmed: 22629509
Clin Breast Cancer. 2018 Apr;18(2):144-149
pubmed: 29290565
BMC Cancer. 2018 Jul 30;18(1):770
pubmed: 30060745
Arq Bras Endocrinol Metabol. 2012 Feb;56(1):1-5
pubmed: 22460188
J Clin Oncol. 2009 Aug 1;27(22):3605-10
pubmed: 19546403
Eur J Surg Oncol. 2009;35 Suppl 1:1-22
pubmed: 19299100
Osteoporos Int. 2011 Jan;22(1):231-40
pubmed: 20556359
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
Nutr J. 2011 Jan 06;10:3
pubmed: 21211048
J Clin Endocrinol Metab. 1990 Apr;70(4):1007-13
pubmed: 2156883
J Clin Oncol. 2009 May 1;27(13):2151-6
pubmed: 19349547
Breast Cancer Res Treat. 2012 Jul;134(2):709-17
pubmed: 22562178
Am J Clin Nutr. 2007 Mar;85(3):649-50
pubmed: 17344484